Linksbridge Pharma: this week's highlights
Each week, Linksbridge covers industry and R&D developments important to global health. From early-stage vaccines to multistakeholder initiatives supporting market health, we tell you what’s happening and why it matters. To access full coverage, sign up today.
Our team will publish a special edition this Friday with highlights from the 25th International AIDS Conference in Munich.
Valneva scores $41M to boost chikungunya vaccine access
CEPI and the European Union have added up to $41.3 million to their investment in Valneva’s Ixchiq chikungunya vaccine, this time to help broaden LMIC access and assess the live attenuated jab in at-risk populations.
In an announcement Monday, CEPI said the five-year award will go toward post-marketing trials in vulnerable groups, including children ages 1-11 and pregnant women. Some of the funds will also support tech transfer of the single-dose shot to an additional vaccine manufacturer to accelerate access in Asian LMICs vulnerable to chikungunya outbreaks, the press release said.
Merck RSV mAb shows late-stage promise
Merck’s prophylactic RSV monoclonal antibody for infants met primary endpoints in a Phase 2b/3 trial, the multinational announced Wednesday.
Topline results showed that a dose of clesrovimab reduced medically attended lower respiratory infections caused by RSV through day 150, the press release said. The trial involved over 3,600 pre- or full-term infants.
Additional stories from our July 24 issue:
For full coverage of pharma, vaccines, AMR, and health campaign news, sign up for Linksbridge newsletters today.